Cooperative Agreement NU58DP006079

This federal Project Grant award of $622,913 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program will fund a 5-year study to evaluate a multilevel intervention to increase colonoscopic follow-up after abnormal stool-based colorectal cancer screening in a community safety-net setting. The study will be conducted by the University of California, Los Angeles (UCLA) in partnership with the Northeast Valley Health Corporation (NEVHC), a...

This federal Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) provides $197,640 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop implementation strategies to initiate colorectal cancer (CRC) screening in previously unscreened individuals aged 45 to 54 at a predominantly Black community health center in Boston, Massachusetts. The key objectives are to: (1) identify system-level determinants of...

This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), will support the development and clinical validation of an Optical Coherence Tomography (OCT) system and two specialized OCT imaging probes to enhance colorectal cancer screening. The $1,471,777 award to The General Hospital Corporation (doing business as Massachusetts General Hospital) aims to create an OCT system that can obtain 3D microscopic images of...

This $753,446 Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) aims to develop and evaluate an intervention to improve cervical cancer screening and follow-up in three diverse, underserved populations: urban inner city Blacks/Haitians in Boston, Hispanic immigrants in Florida, and Hawaiian Natives/Pacific Islanders in Hawaii. The intervention, called DOSE-CC, combines education and quality improvement methods using a performance...

The National Cancer Institute (NCI) awarded a $5,151,564 Project Grant under the Cancer Centers Support Grants (CFDA 93.397) program to the Fred Hutchinson Cancer Center in Seattle, WA to conduct a Translational Research Program in Colorectal Cancer Disparities. The program aims to reduce persistent racial and ethnic disparities in colorectal cancer (CRC) incidence, mortality, and morbidity, particularly among African American and Alaska Native populations. Key products and services include:...

The National Cancer Institute (NCI) awarded a $447,686 Cooperative Agreement under the Cancer Cause and Prevention Research (CFDA 93.393) federal grant program to the Alaska Native Tribal Health Consortium (ANTHC) and its partner Fred Hutchinson Cancer Center. The goal of this 5-year project is to establish the first community-engaged cohort study to investigate risk factors associated with the high rates of colorectal cancer among Alaska Native people. The project will enroll 1,000...

This Project Grant award from the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research) provides $637,596 to develop and test a video-based intervention to reduce defensive avoidance of colorectal cancer information and increase screening uptake. The research aims to reach people who would typically avoid such health information, which accounts for 20-30% of the general population. The intervention is designed to increase self-efficacy and positive affect, and will be...

This federal Project Grant award from the Health Resources and Services Administration (HRSA) under the Community Health Centers (CFDA 93.224) program provides $500,000 over 2 years to Neighborhood Health, a non-profit healthcare organization in Northern Virginia. The funding will be used to increase breast and colorectal cancer screening rates among the organization's largely low-income, immigrant, and uninsured patient population. Specifically, the project aims to conduct breast cancer...

This Project Grant award for $1,403,822 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) federal grant program will support a multi-center, prospective clinical trial to examine the performance of the Fecal Immunochemical Test (FIT) for colorectal cancer surveillance in Lynch Syndrome patients. The study aims to measure the test characteristics of FIT and evaluate personalized surveillance strategies that integrate non-invasive tests like...

This $547,047 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports a study to test the bundling of multicancer screening, risk assessment, and genetic services navigation for improving cancer screening and outcomes among non-Hispanic Black and Hispanic women. The study will be conducted by Georgetown University and aims to: 1) evaluate the effectiveness of bundled multicancer screening and genetic services...